Pentadeca arginate
PDA, BPC-157 arginate, Pentadeca Arginate Peptide
BPC-157 with a different counterion and a new name, marketed as an upgrade on the strength of a stability claim that has never appeared in a peer-reviewed journal.
Anecdotal
Not approved and not legally marketed for human use. Sold as research material and through compounding channels after BPC-157 was placed on the FDA's Category 2 bulk substances list.
What it is
Pentadeca arginate is BPC-157. Same fifteen amino acid sequence, supplied as an arginine salt rather than an acetate salt.
A counterion is the charged partner a peptide is paired with to make a stable solid. It affects handling and stability. It is not part of the molecule that binds anything, and changing it does not produce a new drug in any pharmacological sense.
Why it appeared
Timing explains this entry better than chemistry does.
BPC-157 was placed on the FDA's Category 2 bulk drug substances list, barring compounding pharmacies from producing it. Pentadeca arginate began appearing shortly afterwards, under a name that does not match the listed substance, sold through the channels BPC-157 had just been excluded from.
That sequence may be coincidence. It is worth knowing when reading claims that this is a next-generation compound.
The evidence position is unusually stark
There is no peer-reviewed study of pentadeca arginate as a distinct molecule. Not a trial, not an animal study, not a pharmacokinetic characterisation. Searches of the literature under this name and its variants return nothing.
The evidence base being cited for it is the BPC-157 literature, which is itself over a hundred rodent papers with, as of a 2025 systematic review that screened 544 papers, a single human study consisting of a twelve patient retrospective case series.
The specific marketing claim that the arginate salt is roughly a thousand times more stable at low pH than the acetate has not been published anywhere. It circulates in compounding pharmacy material and vendor copy, and it originates there.
Practical notes
- Treat it as BPC-157 in every respect. Same sequence, same mechanism, same evidence, same unknowns. If you would not take one, the rename is not a reason to take the other.
- A new name with no literature behind it is a warning sign, not a feature. Novelty in this market frequently means the regulatory attention has not caught up yet rather than that the science has moved.
- The stability argument, even if true, would not change the evidence. A more stable version of a compound with no human efficacy data is a more stable compound with no human efficacy data.
Side effects and warning signs
Commonly reported
- Injection-site irritation
- No systematic human safety dataset exists for this or for BPC-157
Stop and get medical help
- The same considerations as BPC-157 apply, including angiogenic activity in the presence of any malignancy
- Marketing claims that this form is safer or better characterised than BPC-157 are not supported by any published evidence
Sources
From the community
Discussion for this compound concentrates in r/Peptides and r/PeptideAdvice.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.